Ann Martin

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results

Madeleine Duvic, Kenneth B. Hymes, Peter Heald et al. · Journal of Clinical Oncology · 2001 · 701 citations

Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma

Elise A. Olsen, Madeleine Duvic, Arthur E. Frankel et al. · Journal of Clinical Oncology · 2001 · 608 citations

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

H. Miles Prince, Madeleine Duvic, Ann Martin et al. · Journal of Clinical Oncology · 2010 · 231 citations

Immunology, Denileukin Diftitox, Pathology +17

A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin

Elisha Roberson, Ying Liu, Caitriona Ryan et al. · Journal of Investigative Dermatology · 2011 · 160 citations · Full text

Normal Skin, Pathology, Clinical Dermatology +4

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

Peter Heald, Marilyn A. Mehlmauer, Ann Martin et al. · Journal of the American Academy of Dermatology · 2003 · 159 citations

Lymphoid Neoplasia, Topical Bexarotene Therapy, Medicine +5